Zobrazeno 1 - 10
of 63
pro vyhledávání: '"ивабрадин"'
Autor:
Iurii N. Belenkov, Elena V. Privalova, Irina S. Ilgisonis, Iuliia I. Naymann, Alexey V. Zhito
Publikováno v:
КардиоСоматика, Vol 10, Iss 3, Pp 79-84 (2019)
Chronic heart failure is one of the leading causes of mortality among patients with cardiovascular diseases. Current therapeutic methods for treating patients with chronic heart failure do not always provide a significant improvement in main intermed
Externí odkaz:
https://doaj.org/article/a083f2d6a5c043d0884caf783c22d968
Autor:
K. G. Adamyan, A. L. Chilingarian
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 5, Iss 3, Pp 31-35 (2016)
Aim. To compare ivabradine (IB) and verapamil (VP) effects on left ventricle (LV) diastolic function in patients with diastolic heart failure (DHF) caused by left ventricle impaired relaxation.Methods. It was comparative randomized study. 238 patient
Externí odkaz:
https://doaj.org/article/4bd05d716c71458586cc1472d46ddd0a
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 8, Iss 2, Pp 211-219 (2015)
A comparison of ivabradine and omega-3 polyunsaturated fatty acids, drugs with principally different mechanisms of action, is presented in patients with chronic heart failure (CHF) on the base of GISSI-HF and SHIFT trails results. It is essential to
Externí odkaz:
https://doaj.org/article/938ed44d108446cfbf1f15d5ddd7ce70
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 8, Iss 5, Pp 661-666 (2015)
Aim. To assess the changes in blood pressure (BP) circadian profile and variability in patients with chronic heart failure (CHF) of ischemic etiology and arterial hypertension (HT) due to the complex therapy including ivabradine. Material and methods
Externí odkaz:
https://doaj.org/article/654da27f1b914916a549ce143d966f91
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 11, Iss 5, Pp 483-488 (2015)
Aim. To study the efficacy of use of amiodarone with ivabradine combination or amiodarone with bisoprolol combination in the prevention of atrial fibrillation (AF) recurrence in patients (pts) with left ventricular diastolic dysfunction (LVDD) after
Externí odkaz:
https://doaj.org/article/f7b2491b7fe343ce805fefcf3defc5e5
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 11, Iss 1, Pp 79-84 (2015)
Aspects of heart rate-lowering therapy in patients with chronic heart failure using If-channel blocker ivabradine are discussed. The evidence-based data on ivabradine use reveal its advantages, disadvantages and place in the treatment of cardiac pati
Externí odkaz:
https://doaj.org/article/75e6f4218816420f81dc9ed180512fc3
Autor:
E. S. Rokotyanskaya
Publikováno v:
Кубанский научный медицинский вестник, Iss 5, Pp 102-108 (2014)
100 patients with CHF FC III against the background of ischemic heart disease (IHD) and/or stage III hypertensive disease (HD). All them administered of complex therapy (Quinapril, Torasemide, Spironolactone). Upon randomization, Group 1 consisted of
Externí odkaz:
https://doaj.org/article/01335f4b2cb24f6ea29627871b69c2d9
Autor:
E. S. Rokotyanskaya
Publikováno v:
Кубанский научный медицинский вестник, Vol 0, Iss 1, Pp 154-160 (2014)
100 patients with CHF FC III against the background of ischemic heart disease (IHD) and/or stage III hypertensive disease (HD) who received complex therapy (quinapril, torasemide, spironolactone) took part in the research. Upon randomization, Group 1
Externí odkaz:
https://doaj.org/article/b40ed1240cc94d929aad95b74df9788b
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 2, Pp 65-72 (2012)
The aim of study was to assess the efficacy of ivabradine (I, up to 15 mg) therapy on prognosis, right ventricular (RV) and atrial (RA) functional parameters, BNP, NT-pro-BNP and high sensitivity С reactive protein (CRP) levels in patients (pts) wit
Externí odkaz:
https://doaj.org/article/4fcdf5d7126c4c2fb143f5603d3bd722
Publikováno v:
КардиоСоматика, Vol 10, Iss 3, Pp 79-84 (2019)
Chronic heart failure is one of the leading causes of mortality among patients with cardiovascular diseases. Current therapeutic methods for treating patients with chronic heart failure do not always provide a significant improvement in main intermed